Full Text View
Tabular View
No Study Results Posted
Related Studies
Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]
This study has been completed.
Study NCT00268710.   Last updated on July 29, 2008.
Information provided by Sanofi-Aventis
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Prostatic Neoplasms
More general conditions related to this trial
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Interventions listed in this trial
docetaxel
More general drug interventions related to this trial
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Sanofi-Aventis
Canadian Urologic Oncology Group


U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services